Cargando…
Laquinimod Supports Remyelination in Non-Supportive Environments
Inflammatory demyelination, which is a characteristic of multiple sclerosis lesions, leads to acute functional deficits and, in the long term, to progressive axonal degeneration. While remyelination is believed to protect axons, the endogenous-regenerative processes are often incomplete or even comp...
Autores principales: | Nyamoya, Stella, Steinle, Julia, Chrzanowski, Uta, Kaye, Joel, Schmitz, Christoph, Beyer, Cordian, Kipp, Markus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912710/ https://www.ncbi.nlm.nih.gov/pubmed/31683658 http://dx.doi.org/10.3390/cells8111363 |
Ejemplares similares
-
Expression of Translocator Protein and [18F]-GE180 Ligand Uptake in Multiple Sclerosis Animal Models
por: Nack, Anne, et al.
Publicado: (2019) -
Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis
por: Moore, Spencer, et al.
Publicado: (2013) -
Remyelination in Multiple Sclerosis: Findings in the Cuprizone Model
por: Leo, Heinig, et al.
Publicado: (2022) -
Aryl Hydrocarbon Receptor Activation in Astrocytes by Laquinimod Ameliorates Autoimmune Inflammation in the CNS
por: Rothhammer, Veit, et al.
Publicado: (2021) -
Laquinimod Inhibits Inflammation-Induced Angiogenesis in the Cornea
por: Li, Zuohong, et al.
Publicado: (2020)